Shattuck Labs Q1 net loss $24.5M ($0.58/shr); cash $239.2M; SL-172154 dose escalation ongoing

Shattuck Labs, Inc.

2022-Q1 EPS reported -$0.58

Net loss $24.5M ($0.58 per share) vs $11.8M ($0.28) YoY; R&D expenses $19.2M, up from $10.3M.
Cash & short-term investments $239.2M as of Mar 31, 2022, down from $321.2M a year ago; runway into 2H2024.
Phase 1 dose escalation of SL-172154 in ovarian cancer continues; full monotherapy data expected 1H2023.
Combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer on track to start 2H2022.
Phase 1 trial of SL-279252 in solid tumors enrolling; top-line data expected 2H2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.